An Open-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Trial Profile

An Open-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs Rivaroxaban (Primary) ; Aspirin; Clopidogrel; Prasugrel; Ticagrelor; Vitamin K antagonists
  • Indications Thromboembolism
  • Focus Adverse reactions; Registrational
  • Acronyms PIONEER-AF-PCI
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 30 Aug 2017 Results assessing assess the interaction of procedure and lesion characteristics with bleeding and ischemic events among AF patients anticoagulated with rivaroxaban or warfarin, presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology.
    • 30 Aug 2017 Results of strategies to improve out-of-hospital adverse event-free duration data from this study presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
    • 30 Aug 2017 Results estimating whether the cost is associated with rehospitalizations among rivaroxaban based anticoagulation strategies compared with VKA plus DAPT in the PIONEER AF-PCI trial presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top